Cargando…

Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience

Objective: Embryonal tumors with multilayered rosettes (ETMRs) are highly aggressive pediatric brain tumors with poor prognosis. No standard treatment strategy for them exists because of their rarity. This study aimed to share experiences on the clinical diagnosis and treatment of ETMRs at China Chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zengyan, Wu, Zhiming, Dong, Youhong, Zhang, Dongdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600658/
https://www.ncbi.nlm.nih.gov/pubmed/36291496
http://dx.doi.org/10.3390/children9101560
_version_ 1784816897813905408
author Li, Zengyan
Wu, Zhiming
Dong, Youhong
Zhang, Dongdong
author_facet Li, Zengyan
Wu, Zhiming
Dong, Youhong
Zhang, Dongdong
author_sort Li, Zengyan
collection PubMed
description Objective: Embryonal tumors with multilayered rosettes (ETMRs) are highly aggressive pediatric brain tumors with poor prognosis. No standard treatment strategy for them exists because of their rarity. This study aimed to share experiences on the clinical diagnosis and treatment of ETMRs at China Children’s Medical Center (CCMC). Methods: Patients who received a diagnosis of an ETMR between January 2017 and June 2020 were included. Clinical characteristics, such as age of onset, tumor size, stage, tumor site, treatment strategy, and clinical outcome, were retrospectively analyzed. Results: There were four boys and one girl within 4 years who received a diagnosis during this 4-year timeframe, and were thus included. The average age of morbidity was 29 months (range 16–66 months). The common clinical presentation was headaches and nausea caused by intracranial hypertension. All four patients were chromosome 19 microRNA cluster (C19MC) amplification positive. Two patients achieved complete remission, and one patient attained partial remission after multimodal treatment. Of the two deaths, one died from the rapid progression of the disease and another from tumor-related complications. Conclusion: ETMRs are extremely rare brain tumors with a high, early mortality in children. Surgery is the mainstream treatment for ETMRs. Some patients may also benefit from postoperative adjuvant chemotherapy and radiotherapy.
format Online
Article
Text
id pubmed-9600658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96006582022-10-27 Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience Li, Zengyan Wu, Zhiming Dong, Youhong Zhang, Dongdong Children (Basel) Brief Report Objective: Embryonal tumors with multilayered rosettes (ETMRs) are highly aggressive pediatric brain tumors with poor prognosis. No standard treatment strategy for them exists because of their rarity. This study aimed to share experiences on the clinical diagnosis and treatment of ETMRs at China Children’s Medical Center (CCMC). Methods: Patients who received a diagnosis of an ETMR between January 2017 and June 2020 were included. Clinical characteristics, such as age of onset, tumor size, stage, tumor site, treatment strategy, and clinical outcome, were retrospectively analyzed. Results: There were four boys and one girl within 4 years who received a diagnosis during this 4-year timeframe, and were thus included. The average age of morbidity was 29 months (range 16–66 months). The common clinical presentation was headaches and nausea caused by intracranial hypertension. All four patients were chromosome 19 microRNA cluster (C19MC) amplification positive. Two patients achieved complete remission, and one patient attained partial remission after multimodal treatment. Of the two deaths, one died from the rapid progression of the disease and another from tumor-related complications. Conclusion: ETMRs are extremely rare brain tumors with a high, early mortality in children. Surgery is the mainstream treatment for ETMRs. Some patients may also benefit from postoperative adjuvant chemotherapy and radiotherapy. MDPI 2022-10-14 /pmc/articles/PMC9600658/ /pubmed/36291496 http://dx.doi.org/10.3390/children9101560 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Li, Zengyan
Wu, Zhiming
Dong, Youhong
Zhang, Dongdong
Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience
title Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience
title_full Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience
title_fullStr Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience
title_full_unstemmed Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience
title_short Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience
title_sort clinical management of embryonal tumor with multilayered rosettes: the ccmc experience
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600658/
https://www.ncbi.nlm.nih.gov/pubmed/36291496
http://dx.doi.org/10.3390/children9101560
work_keys_str_mv AT lizengyan clinicalmanagementofembryonaltumorwithmultilayeredrosettestheccmcexperience
AT wuzhiming clinicalmanagementofembryonaltumorwithmultilayeredrosettestheccmcexperience
AT dongyouhong clinicalmanagementofembryonaltumorwithmultilayeredrosettestheccmcexperience
AT zhangdongdong clinicalmanagementofembryonaltumorwithmultilayeredrosettestheccmcexperience